BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10585005)

  • 21. Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
    Miller VA
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-15-S14-17. PubMed ID: 9335518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current status of docetaxel for advanced non-small cell lung cancer.
    Green MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Leu KM; Kim KM; Larson M; Larson M; Schiller JH
    Lung Cancer; 2001 Oct; 34(1):105-13. PubMed ID: 11557120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
    Miller VA; Ng KK; Krug LM; Perez W; Pizzo B; Heelan RT; Kris MG
    Cancer; 2000 Mar; 88(5):1045-50. PubMed ID: 10699893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 30. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
    Bennouna J; Monnier A; Rivière A; Milleron B; Lemarie E; Trillet-Lenoir V; Soussan-Lazard K; Berille J; Douillard JY
    Eur J Cancer; 2000 Jun; 36(9):1107-12. PubMed ID: 10854943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
    Kubota K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
    Rigas JR
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):5-9. PubMed ID: 9704669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ifosfamide and docetaxel in non-small cell lung cancer.
    Drings P; Büchholz E; Manegold C
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):29-37. PubMed ID: 9535209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
    Krug LM; Miller VA; Filippa DA; Venkatraman E; Ng KK; Kris MG
    Lung Cancer; 2003 Feb; 39(2):139-43. PubMed ID: 12581565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
    Oncology (Williston Park); 2002 Aug; 16(8):1052. PubMed ID: 12201644
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Matsumura T; Chikamori M; Matsushita A; Kohara H; Harada M
    Anticancer Res; 1999; 19(1A):291-9. PubMed ID: 10226557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study shows 2-year survival advantage for docetaxel.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
    [No Abstract]   [Full Text] [Related]  

  • 38. Docetaxel in combination with doxorubicin or vinorelbine.
    Diéras V; Fumoleau P; Kalla S; Misset JL; Azli N; Pouillart P
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S20-2. PubMed ID: 9486099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lung carcinoma].
    Sutani A; Kobayashi K
    Gan To Kagaku Ryoho; 2006 May; 33(5):590-4. PubMed ID: 16685153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
    Belani C; Lynch T
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):10-4. PubMed ID: 11284619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.